Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 327-332, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vincent-Viry, M.
Right arrow Articles by Siest, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vincent-Viry, M.
Right arrow Articles by Siest, G.

Clinical Chemistry, Vol 37, 327-332, Copyright © 1991 by American Association for Clinical Chemistry

Relation between debrisoquine oxidation phenotype and morphological, biological, and pathological variables in a large population

M Vincent-Viry, J Muller, B Fournier, MM Galteau and G Siest
Laboratoire du Centre de Medecine Preventive et Centre du Medicament, Unite CNRS No. 597, Vandoeuvre-les-Nancy, France.

Factors affecting biological variations in debrisoquine-oxidation polymorphism were investigated in a population of 3065 unrelated supposedly healthy Caucasian subjects, ages 35 to 50 years. This population, including 1526 men and 1539 women, was used to determine whether the debrisoquine-oxidation phenotype can be related with environmental factors such as alcohol intake, smoking habits or medication; with morphological variables; or with 22 blood constituents and some pathological states. A single dose of 10 mg of debrisoquine sulfate was administered to determine the oxidation phenotype. A metabolic ratio (debrisoquine/4-hydroxydebrisoquine) of 10.0 defined a poor metabolizer [frequency of 8.2% (SD 1.0%)] in this sample. Dose recoveries of debrisoquine excretion (mean and SD) were 8.9% (11.9%) and 45.1% (32.2%) in extensive and poor metabolizers, respectively. The mean (SD) amount of debrisoquine administered that was excreted in urine as 4-hydroxydebrisoquine was 17.4% (17.3%) in extensive metabolizers and 0.5% (0.9%) in poor metabolizers. The main factors differing significantly between poor and extensive metabolizers were mean cell volume, mean corpuscular hemoglobin concentration, albumin, and ponderal index. No other blood constituents (e.g., cholesterol, glucose) differed between poor and extensive metabolizers. The lack of correlation with most of the variables tested is of interest in clinical trials, because our findings indicate that no subgroups will be required, making selection of subjects easier.


The following articles in journals at HighWire Press have cited this article:


Home page
 NeurologyHome page
H. Payami, N. Lee, S. Zareparsi, M. Gonzales McNeal, R. Camicioli, T.D. Bird, G. Sexton, S. Gancher, J. Kaye, D. Calhoun, et al.
Parkinson's disease, CYP2D6 polymorphism, and age
Neurology, May 22, 2001; 56(10): 1363 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Vincent-Viry, B. Fournier, and M.-M. Galteau
Short Communication. The Effects of Drinking and Smoking on the CYP2D6 Metabolic Capacity
Drug Metab. Dispos., June 1, 2000; 28(6): 617 - 619.
[Abstract] [Full Text]

Home page
 Ann. N. Y. Acad. Sci.Home page
E. M. SELLERS and R. F. TYNDALE
Mimicking Gene Defects to Treat Drug Dependence
Ann. N.Y. Acad. Sci., January 1, 2000; 909(1): 233 - 246.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.